



March 2020 WORKING GROUP MEETING MINUTES: COPD

Meeting details	
Meeting location	Teleconference
Meeting date	Thursday 19 th March
Meeting time	15:30 CET
Chair(s)	Marc Miravittles
Attendees	Helgo Magnussen David Price Diana Urlichich Bernardino Alcazar Tony D'Urzo Chin Kook Rhee Dermot Ryan Sarah Lucas
Objectives	
1	Update on current projects
2	Future projects
3	New project ideas

Items	
Update on current projects	<p>Validation of the concept of control in COPD (PI Marc Miravittles)</p> <ul style="list-style-type: none">Already published - Baseline manuscript- Asian vs Western sub-analysis <p>The long-term effects of control manuscript has just been accepted in <i>Respirology</i></p> <p>The short-term effects of control manuscript is nearly ready to submit, it has been sent to Novartis for review. Marc is waiting for the long-term effects paper to be published first. Consider sending to <i>Annals</i>, <i>Respiratory Research</i> or <i>eClinical Medicine</i>.</p> <p>Tony did an abstract looking at treatments and control which had been submitted for the REG summit.</p> <p>Action: Marc and Tony to discuss a treatment manuscript.</p>



	<p>Real- life WISDOM (PI Helgo Magnussen)</p> <p>Initial results were discussed. It was suggested to try using matching rather than just multivariate analysis to account for the differences in severity between the two groups.</p> <p>We will try direct matching (if not propensity score matching). Look at standardised mean differences. Consider matching on baseline exacerbation number, sex, age, smoking status and potentially mMRC score and FEV1 % predicted.</p> <p>Asthma diagnosis prebaseline, exacerbation group and eosinophils should be investigated as potential effect modifiers.</p> <p>Action: Sarah to re-run the analysis with matching</p> <p>Discussed different results in terms of the effect of triple vs dual therapy in RCTs, prospective and retrospective studies. Also, the issues with some patients in these studies having undiagnosed/ unrecorded asthma and there will be a mix of patients, particularly in primary care.</p> <hr/> <p>Peak Inspiratory Flow in COPD (PI Omar Usmani)</p> <p>Update on progress</p> <ul style="list-style-type: none">- Marc has made the initial ethics application to his centre as Omar who is now CI will not be recruiting at his centre. Waiting on ethics approval but we do not foresee any issues.- BioClever have been contracted as the CRO for this study.- CRF has been prepared and is to be sent to the CRO for programming of the eCRF.- REG have been looking into the purchasing of PIF devices and arranging training materials.- Currently recruiting centres, we have about 10 but need at least 20, as we will need 400 patients. <p>Actions: Sarah will send information to Tony regarding the study to see if they may be able to participate in N. America, but may depend if there are issues with the ethics. Marc/ Bernardino to see if there is anyone else in Spain they can recruit. Omar as CI to recruit some additional sites.</p> <p>If anyone wants to take part/knows anyone who may be interested/has any suggestions, please let us know.</p>
Future projects	Epidemiology and characterisation of the natural history of alpha1-antitrypsin deficiency (AATD) in the UK (PI Joan Soriano)



	<p>We have revised the proposal for this project. Originally we planned to use data from both OPCR and CPRD, but it is looking like we will have to use only CPRD as we will need Hospital Episode Statistics and Office of National Statistics mortality data, and data linkage is not currently available for OPCR.</p> <p>Action: REG and Joan to discuss and begin seeking funding</p>
New projects	<p>Any ideas for future projects please let us know.</p>